Cervical cancer screening by high risk HPV testing in routine practice: results at one year recall of high risk HPV-positive and cytology-negative women

Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study

(2013) M Zorzi et al.   BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY

Clinical Impact of the Analytical Specificity of the Hybrid Capture 2 Test: Data from the New Technologies for Cervical Cancer (NTCC) Study

(2013) A. Gillio-Tos et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Five-Year Risks of CIN 3+ and Cervical Cancer Among WomenWho Test Pap-Negative But Are HPV-Positive

(2013) Hormuzd A. Katki et al.   Journal of Lower Genital Tract Disease

Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial

(2012) Francesca Carozzi et al.   LANCET ONCOLOGY

New Technologies and Procedures for Cervical Cancer Screening

(2012) Jack Cuzick et al.   VACCINE

Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening

(2011) Dorien C. Rijkaart et al.   INTERNATIONAL JOURNAL OF CANCER

European Guidelines for Quality Assurance in Cervical Cancer Screening. Second Edition--Summary Document

(2010) M. Arbyn et al.   ANNALS OF ONCOLOGY

Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study

(2010) D Mesher et al.   BRITISH JOURNAL OF CANCER

Incomplete follow-up of positive HPV tests: overview of randomised controlled trials on primary cervical screening

(2010) M Rebolj et al.   BRITISH JOURNAL OF CANCER

Screening for Cervical Cancer with the Human Papillomavirus Test in an Area of Central Italy with No Previous Active Cytological Screening Programme

(2010) Massimo Confortini et al.   JOURNAL OF MEDICAL SCREENING

Longitudinal Study of Human Papillomavirus Persistence and Cervical Intraepithelial Neoplasia Grade 2/3: Critical Role of Duration of Infection

(2010) A. C. Rodriguez et al.   JNCI-Journal of the National Cancer Institute

Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China

(2010) Fang-Hui Zhao et al.   LANCET ONCOLOGY

Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial

(2010) Guglielmo Ronco et al.   LANCET ONCOLOGY

Age-Specific Evaluation of Primary Human Papillomavirus Screening vs Conventional Cytology in a Randomized Setting

(2009) Maarit Leinonen et al.   JNCI-Journal of the National Cancer Institute

Efficacy of HPV DNA Testing With Cytology Triage and/or Repeat HPV DNA Testing in Primary Cervical Cancer Screening

(2009) P. Naucler et al.   JNCI-Journal of the National Cancer Institute

HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial

(2009) Henry C Kitchener et al.   LANCET ONCOLOGY

Test positivity cutoff level of a high risk human papillomavirus test could be increased in routine cervical cancer screening

(2008) Laura Kotaniemi-Talonen et al.   INTERNATIONAL JOURNAL OF CANCER

Results at Recruitment From a Randomized Controlled Trial Comparing Human Papillomavirus Testing Alone With Conventional Cytology as the Primary Cervical Cancer Screening Test

(2008) G. Ronco et al.   JNCI-Journal of the National Cancer Institute